JKJohannes Anthon Kroes

Johannes Anthon Kroes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Johannes Anthon Kroes has a total of 117 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Delayed cardiac arrest after hydrofluoric acid ingestion

    by J. A. Kroes, J. M. H de Haan, M. I. de Haan-Lauteslager, E. N. van Roon, S. J. Derksen, E. R. Manusama, G. J. Zijlstra, S. S. Gisbertz, B. E. L Vrijsen, C. Bethlehem


  • Open Access

    The perceived waning of biologics in severe asthma

    by J.A. Kroes, L.H.G. Van Hal, L. Van Dijk, S.W. Zielhuis, A.N. Van Der Meer, E.N. Van Roon, A. Ten Brinke


  • Open Access

    Characteristics of severe asthma patients on biologics: a real-life European registry study

    by Stefania Principe, Levi B. Richards, Simone Hashimoto, Johannes Anthon Kroes, Job J. M. H. Van Bragt, Susanne J. Vijverberg, Jacob K. Sont, Nicola Scichilone, Kristina Bieksiene, Anneke Ten Brinke, et al.

    Background: The use of anti-interleukin-5 (IL5) for severe asthma is based on criteria from randomised controlled trials (RCTs), but in real-life patients might not fulfil the eligibility criteria but may benefit from biologics. We aimed to characterise patients starting anti-IL5(R) in Europe and evaluate the discrepancies between initiation of anti-IL5(R) in real life and in RCTs.Materials and methods: We performed a cross-sectional analysis with data from the severe asthma patients at the start of anti-IL5(R) in the Severe Heterogeneous Asthma Research collaboration Patient-centred (SHARP Central) registry. We compared the baseline characteristics of the patients starting anti-IL5(R) from 11 European countries within SHARP with the baseline characteristics of the severe asthma patients from 10 RCTs (four for mepolizumab, three for benralizumab and three for reslizumab). Patients were evaluated following eligibility criteria from the RCTs of anti-IL5 therapies.Results: Patients starting anti-IL5(R) in Europe (n=1231) differed in terms of smoking history, clinical characteristics and medication use. The characteristics of severe asthma patients in the SHARP registry differed from the characteristics of patients in RCTs. Only 327 (26.56%) patients fulfilled eligibility criteria of all the RCTs; 24 patients were eligible for mepolizumab, 100 for benralizumab and 52 reslizumab. The main characteristics of ineligibility were: ≥10 pack-years, respiratory diseases other than asthma, Asthma Control Questionnaire score ≤1.5 and low-dose inhaled corticosteroids.Conclusion: A large proportion of patients in the SHARP registry would not have been eligible for anti-IL5(R) treatment in RCTs, demonstrating the importance of real-life cohorts in describing the efficacy of biologics in a broader population of patients with severe asthma.


  • Open Access

    Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis

    by Johannes A. Kroes, Rafael Alfonso-Cristancho, Aruna T. Bansal, Emmanuelle Berret, Kristina Bieksiene, Arnaud Bourdin, Luisa Brussino, Diogo Canhoto, Cristina Cardini, Gulfem Celik, et al.

    Background: An objective of the Severe Heterogeneous Asthma Registry, Patient-centered (SHARP) is to produce real-world evidence on a pan-European scale by linking nonstandardised, patient-level registry data. Mepolizumab has shown clinical efficacy in randomised controlled trials and prospective real-world studies and could therefore serve as a proof of principle for this novel approach. The aim of the present study was to harmonise data from 10 national severe asthma registries and characterise patients receiving mepolizumab, assess its effectiveness on annual exacerbations and maintenance oral glucocorticoid (OCS) use, and evaluate treatment patterns. Methods: In this observational cohort study, registry data (5871 patients) were extracted for harmonisation. Where harmonisation was possible, patients who initiated mepolizumab between 1 January 2016 and 31 December 2021 were examined. Changes of a 12-month (range 11–18 months) period in frequent (two or more) exacerbations, maintenance OCS use and dose were analysed in a privacy-preserving manner using meta-analysis of generalised estimating equation parameters. Periods before and during the coronavirus disease 2019 pandemic were analysed separately. Results: In 912 patients who fulfilled selection criteria, mepolizumab significantly reduced frequent exacerbations (OR 0.18, 95% CI 0.13–0.25), maintenance OCS use (OR 0.75, 95% CI 0.61–0.92) and dose (mean −3.93 mg·day −1 , 95% CI −5.24–2.62 mg·day −1 ) in the pre-pandemic group, with similar trends in the pandemic group. Marked heterogeneity was observed between registries in patient characteristics and mepolizumab treatment patterns. Conclusions: By harmonising patient-level registry data and applying federated analysis, SHARP demonstrated the real-world effectiveness of mepolizumab on asthma exacerbations and maintenance OCS use in severe asthma patients across Europe, consistent with previous evidence. This paves the way for future pan-European real-world severe asthma studies using patient-level data in a privacy-proof manner.


  • Open Access

    Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics

    by Johannes A. Kroes, Kim de Jong, Simone Hashimoto, Sander W. Zielhuis, Eric N. van Roon, Jacob K. Sont, Anneke Ten Brinke

    Background: Benralizumab is highly effective in many, but not all, patients with severe asthma. Baseline characteristics alone are insufficient to predict an individual's probability of long-term benralizumab response. The objectives of the present study were to: 1) study whether parameters at 3 months, in addition to baseline characteristics, contribute to the prediction of benralizumab response at 1 year; and 2) develop an easy-to-use prediction tool to assess an individual's probability of long-term response.Methods: We assessed the effect of benralizumab treatment in 192 patients from the Dutch severe asthma registry (RAPSODI). To investigate predictors of long-term benralizumab response (≥50% reduction in maintenance oral corticosteroid (OCS) dose or annual exacerbation frequency) we used logistic regression, including baseline characteristics and 3-month Asthma Control Questionnaire (ACQ-6) score and maintenance OCS dose.Results: Benralizumab treatment significantly improved several clinical outcomes, and 144 (75%) patients were classified as long-term responders. Response prediction improved significantly when 3-month outcomes were added to a predictive model with baseline characteristics only (area under the receiver-operating characteristic (AUROC) 0.85versus0.72, p=0.001). Based on this model, a prediction tool using sex, prior biologic use, baseline blood eosinophils, forced expiratory volume in 1 s, and at 3 months OCS dose and ACQ-6 was developed which classified patients into three categories with increasing probability of long-term response (95% CI): 25% (3–65%), 67% (57–77%) and 97% (91–99%), respectively.Conclusion: In addition to baseline characteristics, treatment outcomes at 3 months contribute to the prediction of benralizumab response at 1 year in patients with severe eosinophilic asthma. Prediction tools as proposed in this study may help physicians optimise the use of costly biologics.


  • Open Access

    Cumulative corticosteroid-sparing effect of anti-interleukin-5/5Ra in eosinophilic asthma

    by Johannes A. Kroes, Sybrand W.J. Zielhuis, Kim De Jong, Simone Hashimoto, Jacob K. Sont, Eric N. Van Roon, Elisabeth H. Bel, Anneke Ten Brinke

    Background: Anti-interleukin (IL)-5/IL-5 receptor α (IL-5Ra) therapy has been shown to reduce maintenance oral corticosteroid (OCS) dose in severe eosinophilic asthma. However, the effect on cumulative OCS exposure is currently unknown. Neither is it known how prior OCS exposure affects response to anti-IL-5/5Ra treatment. We aimed primarily to compare the cumulative OCS exposure over a 2-year period before and after anti-IL-5/5Ra initiation, and secondarily to investigate whether duration and cumulative OCS exposure prior to anti-IL-5/5Ra influence the ability to discontinue OCS within 2 years of anti-IL-5/5Ra therapy.Methods: This real-world nationwide observational registry-based study evaluated all dispensed OCS from 389 adults with severe eosinophilic asthma included in the Dutch Severe Asthma Registry (RAPSODI) 2 years before and 2 years after initiating anti-IL-5/5Ra. The Wilcoxon signed-rank test and multivariable regression analyses were used.Results: Median (interquartile range) cumulative OCS exposure in the 2 years before and after anti-IL-5/5Ra initiation decreased from 2.715 (1.150–5.539) to 1.050 (0.300–3.640) g (p<0.001). 52% of patients were able to discontinue OCS within 2 years after anti-IL-5/5Ra therapy, which was independently predicted by lower and shorter prior OCS exposure.Conclusions: This real-world study showed that anti-IL-5/5Ra therapy leads to a significant reduction in cumulative OCS exposure over a 2-year period. Patients with lower and shorter OCS exposure were more likely to completely eliminate OCS. Since cumulative exposure increased progressively prior to anti-IL-5/5Ra initiation, our data suggest that early intervention leads to a better long-term prognosis in patients with severe eosinophilic asthma.


  • Open Access

    Blueprint for harmonising unstandardised disease registries to allow federated data analysis: prepare for the future

    by Johannes A. Kroes, Aruna T. Bansal, Emmanuelle Berret, Nils Christian, Andreas Kremer, Anna Alloni, Matteo Gabetta, Chris Marshall, Scott Wagers, Ratko Djukanovic, et al.

    Real-world evidence from multinational disease registries is becoming increasingly important not only for confirming the results of randomised controlled trials, but also for identifying phenotypes, monitoring disease progression, predicting response to new drugs and early detection of rare side-effects. With new open-access technologies, it has become feasible to harmonise patient data from different disease registries and use it for data analysis without compromising privacy rules. Here, we provide a blueprint for how a clinical research collaboration can successfully use real-world data from existing disease registries to perform federated analyses. We describe how the European severe asthma clinical research collaboration SHARP (Severe Heterogeneous Asthma Research collaboration, Patient-centred) fulfilled the harmonisation process from nonstandardised clinical registry data to the Observational Medical Outcomes Partnership Common Data Model and built a strong network of collaborators from multiple disciplines and countries. The blueprint covers organisational, financial, conceptual, technical, analytical and research aspects, and discusses both the challenges and the lessons learned. All in all, setting up a federated data network is a complex process that requires thorough preparation, but above all, it is a worthwhile investment for all clinical research collaborations, especially in view of the emerging applications of artificial intelligence and federated learning.


  • Open Access

    Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma – First Initiators and Switchers

    by Simone Hashimoto, Johannes A. Kroes, Katrien A. Eger, Pearl F. Mau Asam, Hendrik B. Hofstee, Sarah A. Bendien, Gert Jan Braunstahl, Marielle E.A.C. Broeders, Leonie M. Imming, Bas Langeveld, et al.


  • Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study

    by Johannes Anthon Kroes, Sander Wilhelm Zielhuis, Akke-Nynke van der Meer, Kim de Jong, Anneke Ten Brinke, Eric Nico van Roon

    Background The novel anti-IL-5 drug mepolizumab improves asthma outcomes in the majority but not all patients with severe eosinophilic asthma. Currently it is difficult to predict an individuals’ chance of being a responder. Early changes in patient-reported outcome measures may contribute to the prediction of long-term outcomes. Aim To compare early changes in patient-reported outcome measures after 8 weeks and long-term response to mepolizumab treatment. Method 22 severe eosinophilic asthma patients starting mepolizumab therapy in a severe asthma centre in the Netherlands were evaluated on baseline, 8 weeks and 52 weeks, collecting questionnaire scores and asthma-related parameters. Well-controlled asthma was defined as an asthma control questionnaire score ≤ 0.75. Long-term treatment response was defined as continuing mepolizumab therapy at 52 weeks. Results Nine patients (41%) had well-controlled asthma at 8 weeks and all were mepolizumab responders at 52 weeks (positive predictive value = 100%, 95%CI 66–100), versus only 5 responders out of 13 patients with not well-controlled asthma at 8 weeks (negative predictive value = 62%, 95%CI 32–86). Conclusion The results in this study suggest that patients receiving mepolizumab therapy with an ACQ-score ≤ 0.75 at 8 weeks are unlikely to need extensive monitoring, for they are very likely to be long-term responders.


  • Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy

    by Johannes A Kroes, Sybrand W J Zielhuis, Kim De Jong, Eric N Van Roon, Elisabeth H D Bel, Anneke Ten Brinke

    Background: Prolonged use of oral corticosteroids (OCS) is associated with serious side effects. Anti-interleukin (IL)-5 biologics reduce maintenance dose and number of OCS bursts in severe eosinophilic asthma patients. However, little is known about OCS use over time and the effect of anti-IL-5 therapy on cumulative OCS exposure. Aim: To compare the course and cumulative exposure to OCS in severe eosinophilic asthma patients 2 yr pre and post anti-IL-5 initiation. Methods: Data from 389 patients who started anti-IL-5 biologics (mepolizumab, reslizumab, benralizumab) before January 2019 were obtained from the Dutch Severe Asthma Registry RAPSODI. Pharmacy dispensing data of OCS for 2 yr pre and post anti-IL-5 initiation were obtained from patients9 pharmacies. Results: Cumulative OCS exposure increased from median (IQR) 145 (0-517.62) to 450 (12.5-903.21) mg over 2 yr prior to anti-IL-5 initiation (p<0.001). This increase was mainly observed in the 174 patients not yet using OCS at t= -2 yr. After initiation of anti-IL-5, median OCS exposure decreased by 72% within 6 months. Overall, cumulative OCS exposure decreased from median (IQR) 2715 (1150-5539) to 1050 (300-3640) mg over 2 yr pre and post anti-IL-5 initiation, resp. (p<0.001). Of the patients with an OCS exposure 1 yr (p<0.001). Conclusion: OCS exposure increases markedly over 2 yr in patients with severe eosinophilic asthma. Overall, anti-IL-5 therapy reduces cumulative OCS exposure by about 60%. However, patients with shorter duration of OCS exposure are more likely to eliminate OCS, which argues for early anti-IL-5 intervention.